RSS-Feed abonnieren
DOI: 10.1055/s-2007-966186
© Georg Thieme Verlag Stuttgart · New York
Aktuelle Diagnostik und Therapie des Magenkarzinoms
Publikationsverlauf
Publikationsdatum:
02. April 2007 (online)
![](https://www.thieme-connect.de/media/gastroenterologie-u2d/200701/lookinside/thumbnails/10.1055-s-2007-966186-1.jpg)
Einleitung
Karzinome des Magens und gastroösophagealen Übergangs gehören weltweit zu den häufigsten tumorbedingten Todesursachen. Denn trotz kurativer Resektion zeigen Patienten bereits in frühen Stadien II - III ein schlechtes 5-Jahres-Überleben mit einem hohen Risiko für ein Lokalrezidiv, lymphogene Mikrometastasen oder organische Fernmetastasierung. Zusätzlich steigt die Inzidenz der Kardia- und Barrett-Karzinome.
Da sich in den letzten Jahren aber zahlreiche positive Änderungen in Diagnostik und Therapie ergeben haben, stellen diese Karzinome heute eine Herausforderung für gastroenterologisch tätige Internisten und den überweisenden Hausarzt dar. Aufgrund zahlreicher etablierter interdisziplinärer Therapiekonzepte und der Gründung organbezogener Tumorzentren ist der klassische Überweisungsweg vom Hausarzt zum Gastroenterologen und danach zum Chirurgen nicht mehr ausreichend.
Die neoadjuvanten, adjuvanten und palliativen Therapiestrategien, die im Laufe der letzten Jahre entwickelt wurden, werden in diesem Artikel daher nach Stadien getrennt diskutiert.
Literatur
- 1 Bollschweiler E. et al . High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy. 2006; 38 149-156
- 2 Bollschweiler E. et al . Staging of esophageal carcinoma: lenght of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?. J Surg Oncol. 2006; 94 355-363
- 3 Nagano H. et al . Indications for gastrectomy after incomplete EMR for early gastric cancer. Gastric Cancer. 2005; 8 149-154
- 4 Deutschland A.B.-b. K.i .Krebs in Deutschland, Häufigkeiten und Trends. Saarbrücken; Verlag 2000: 24-26
- 5 Neugut A I, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol. 1996; 23 281-291
- 6 Sawada T, Muto T. Familial adenomatous polyposis: should patients undergo surveillance of the upper gastrointestinal tract?. Endoscopy. 1995; 27 6-11
- 7 Park W S. et al . Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res. 1999; 59 4257-4260
- 8 Messmann H, Schlottmann K. Role of endoscopy in the staging of esophageal and gastric cancer. Semin Surg Oncol. 2001; 20 78-81
- 9 Ziegler K. et al . Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma. Gut. 1993; 34 604-610
- 10 Siewert J R, Stein H J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998; 85 1457-1459
- 11 Cuschieri A. et al . Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999; 79 1522-1530
- 12 Bonenkamp J J. et al . Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World J Surg. 1993; 17 410-414; discussion 415
- 13 Bottcher K. et al . [Risk of surgical therapy of stomach cancer in Germany. Results of the German 1992 Stomach Cancer Study. German Stomach Cancer Study Group (‘92)]. Chirurg. 1994; 65 298-306
- 14 Falcone A. Future strategies and adjuvant treatment of gastric cancer. Ann Oncol. 2003; 14(Suppl 2) ii45-47
- 15 Macdonald J S. et al . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345 725-730
- 16 Lee J H, Han H S, Kim Y W. et al . Laparoscopic wedge resection with handsewn closure for gastroduodenal tumors. J Laparoendosc Adv Surg Tech A. 2003; 13 349-353
- 17 Tada M, Tanaka Y, Matsuo N. et al . Mucosectomy for gastric cancer: current status in Japan. J Gastroenterol Hepatol. 2000; 15(Suppl) D98-102
- 18 Takeo Y. et al . Endoscopic mucosal resection for early esophageal cancer and esophageal dysplasia. Hepatogastroenterology. 2001; 48 453-457
- 19 Ono H. Endoscopic submucosal dissection for early gastric cancer. Chin J Dig Dis. 2005; 6 119-121
- 20 Kunisaki C. et al . Appropriate lymph node dissection for early gastric cancer based on lymph node metastases. Surgery. 2001; 129 153-157
- 21 Gotoda T. et al . Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000; 3 219-225
- 22 Janunger K G, Hafstrom L, Nygren P. et al . A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol. 2001; 40 309-326
- 23 Cunningham D. et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355 11-20
- 24 Menges M. et al . Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate. J Cancer Res Clin Oncol. 2003; 129 423-429
- 25 Ajani J A. et al . Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006; 24 3953-3958
- 26 Klautke G. et al . Neoadjuvant radiochemotherapy in locally advanced gastric carcinoma. Strahlenther Onkol. 2004; 180 695-700
- 27 Moehler M, Schimanski C C, Gockel I. et al . (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change?. Dig Dis. 2004; 22 345-350
- 28 Hohler T, Mohler M. [New chemotherapeutic options in advanced gastric cancer]. Onkologie. 2003; 26(Suppl 7) 54-59
- 29 Webb A. et al . Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15 261-267
- 30 Ross P. et al . Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002; 20 1996-2004
- 31 Vanhoefer U. et al . Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000; 18 2648-2657
- 32 Gadgeel S M. et al . Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol. 2003; 26 37-41
- 33 Van Cutsem E. et al . Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24 4991-4997
- 34 Roth A D, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol. 2003; 14(Suppl 2) ii41-44
- 35 Boku N. et al . Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol. 1999; 17 319-323
- 36 Moehler M. et al . Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer. 2005; 92 2122-2128
- 37 Bouche O. et al . Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J Clin Oncol. 2004; 22 4319-4328
- 38 Al-Batran S E. et al . Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004; 22 658-663
- 39 Wagner A D, Grothe W, Haerting J. et al . Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24 2903-2909; Review
PD Dr. Markus Möhler
Johannes-Gutenberg Universität Mainz
I. Medizinische Klinik und Poliklinik
Langenbeckstraße 1
55101 Mainz
eMail: moehler@mail.uni-mainz.de